New cochlear implant features aim to cut through noise

NCT ID NCT07213505

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested two new features in the MED-EL SONNET 3 audio processor for cochlear implant users: the Focused Beamformer, which improves directional hearing, and the AI Mode Medium, which uses adaptive intelligence to optimize sound processing. Forty experienced cochlear implant users participated to see if these features help them understand speech better in noisy settings. The goal is to make hearing in challenging environments easier for people with hearing loss.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
new front-end features (Focused Beamformer and AI Mode Medium) in the MED-EL SONNET 3 audio processor
What this could lead to
If successful, these features could help cochlear implant users hear better in noisy environments, making conversations easier in places like restaurants or parties.
What could go wrong
This is a small, completed study with only 40 participants, so results may not apply to all users. The improvements are incremental and may not be noticeable in everyday life.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COCHLEAR IMPLANT USERS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Medizinische Universität Innsbruck, Universitätsklinik für Hör-, Stimm-, und Sprachstörungen

    Innsbruck, Austria

  • Universitätsklinikum St. Pölten, Abteilung für Hals-, Nasen- und Ohrenerkrankungen

    Sankt Pölten, Austria

More trials for these conditions

Other studies related to the condition(s) this trial covers.